Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors

Clinical Nuclear Medicine

Volumn 30, Issue 3, 2005, Pages 170-176

  Uchida, Yoshitaka ^d   Minoshima, Satoshi ^a   Kawata, Tetsuya ^e   Motoori, Ken ^e   Nakano, Koichi ^b   Kazama, Toshiki ^c   Uno, Takashi ^e   Okamoto, Yoshitaka ^d   Ito, Hisao ^e  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHIBA AOBA MUNICIPAL HOSPITAL   (Japan)

^c Numazu Municipal Hospital   (Japan)

^d CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NONE

Author keywords

Diagnosis; F 18 FDG PET; Parotid tumor; Salivary grand scintigraphy; Sensitivity

Indexed keywords

CITRIC ACID; FLUORODEOXYGLUCOSE F 18; GALLIUM; GALLIUM CITRATE GA 67; PERTECHNETIC ACID TC 99M;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PAROTID GLAND CANCER; PAROTID GLAND TUMOR; POSITRON EMISSION TOMOGRAPHY; RELIABILITY; SALIVARY GLAND SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; WARTHIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PAROTID NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 13944255722     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200503000-00005     Document Type: Article

References (23)

1. Shinohara S, Yamamoto E, Tanabe M, et al. Evaluation of RI scintiscanning to parotid gland tumors. Nippon Jibiinkoka Gakkai Kaiho. 2001;104:852-858.
2. Shah GV. MR imaging of salivary glands. Magn Reson Imaging Clin North Am. 2002;10:631-662.
3. Wong DS, Li GK. The role of fine-needle aspiration cytology in the management of parotid tumors: a critical clinical appraisal. Head Neck. 2000;22:469-473.
4. Touquet R, Mackenzie IJ, Carruth JA. Management of the parotid pleomorphic adenoma, the problem of exposing tumor tissue at operation. The logical pursuit of treatment policies. Br J Oral Maxillofac Surg. 1990;28:404-408.
5. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S82-S88.
6. Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78-84.
7. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitations in 'clinical reality'. Ann Nucl Med. 2003;17:261-279.
8. Keyes JW Jr, Harkness BA, Greven KM, et al. Salivary gland tumors: pretherapy evaluation with PET. Radiology. 1994;192:99-102.
9. Miyake H, Matsumoto A, Hori Y, et al. Warthin's tumor of parotid gland on Tc-99m pertechnetate scintigraphy with lemon juice stimulation: Tc-99m uptake, size, and pathologic correlation. Eur Radiol. 2001;11: 2472-2478.
10. Horiuchi M, Yasuda S, Shohtsu A, et al. Four cases of Warthin's tumor of the parotid gland detected with FDG PET. Ann Nucl Med. 1998;12: 47-50.
11. Stewart CJ, MacKenzie K, McGarry GW, et al. Fine-needle aspiration cytology of salivary gland: a review of 341 cases. Diagn Cytopathol. 2000;22:139-146.
12. Bartels S, Talbot JM, DiTomasso J, et al. The relative value of fine-needle aspiration and imaging in the preoperative evaluation of parotid masses. Head Neck. 2000;22:781-786.
13. Zbaren P, Schar C, Hotz MA, et al. Value of fine-needle aspiration cytology of parotid gland masses. Laryngoscope. 2001;111:1989-1992.
14. Donovan DT, Conley JJ. Capsular significance in parotid tumor surgery: reality and myths of lateral lobectomy. Laryngoscope. 1984;94:324-329.
15. Dykun RJ, Deitel M, Borowy ZJ, et al. Treatment of parotid neoplasms. Can J Surg. 1980;23:14-19.
16. Myssiorek D, Ruah CB, Hybels RL. Recurrent pleomorphic adenomas of the parotid gland. Head Neck. 1990;12:332-336.
17. Jabour BA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology. 1993;186:27-35.
18. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/ MRI. Nuklearmedizin. 1999;38:312-318.
19. Adams S, Baum RP, Stuckensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med. 1998; 25:1255-1260.
20. Okamura T, Kawabe J, Koyama K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl. 1998;538:209-213.
21. McGuirt WF, Keyes JW Jr, Greven KM, et al. Preoperative identification of benign versus malignant parotid masses, a comparative study including positron emission tomography. Laryngoscope. 1995;105:579-584.
22. Matsuda M, Sakamoto H, Okamura T, et al. Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland. Acta Otolatyngol Suppl. 1998;538:214-220.
23. Motoori K, Yamamoto S, Ueda T, et al. Inter- and intratumoral variability in magnetic resonance imaging of pleomorphic adenoma: an attempt to interpret the variable magnetic resonance findings. J Comput Assist Tomogr. 2004;28:233-246.